Drug Trial Radar · NCT04886765
A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma
Last checked: Nov 20, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
238
Planned (sponsor's estimate)
Start
May 2021
Primary completion
Nov 2023
Study completion May 2024
Sponsor
- Lead sponsor
- AlaMab Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- First posted
- May 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I / II, multi-center, single-arm, open-label study to evaluate the safety and efficacy of ALMB-0168 in patients with osteosarcoma whose prior standard treatment have failed.
Conditions
- Osteosarcoma
Interventions
ALMB-0168Drug
ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: From enrollment to 28 days after the last dose in each part study.
- Dose-Limited Toxicities (DLT)Time frame: Up to 21 days in Cycle 1
- 6-Month Progression-free Survival Rate (6m-PFSR)Time frame: From enrollment to 6 month after the first dose of the last patient in PART II
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.